Global Erectile Dysfunction Drugs Industry

NEW YORK, June 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Erectile Dysfunction Drugs industry

http://www.reportlinker.com/p0197172/Global-Erectile-Dysfunction-Drugs-industry.html

This report analyzes the worldwide markets for Erectile Dysfunction Drugs in US$ Million. The report provides separate comprehensive analytics for US, Canada, Japan, Europe, and Rest of the World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 26 companies including many key and niche players worldwide such as Abbott Laboratories, Eli Lilly and Company, Inc., F. Hoffmann-La Roche, Inc., GlaxoSmithKline plc, Nexmed, Inc., Pfizer, Inc., Sanofi-aventis SA, Vivus, Inc., and Warner Chilcott Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ERECTILE DYSFUNCTION DRUGS MCP-6161

A GLOBAL MARKET REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

Market Scenario II-1

Current & Future Analysis II-1

Challenges II-1

Opportunity for Novel Therapies II-2

Competitive Scenario II-2

Major Drugs II-2

Viagra (sildenafil) II-2

Cialis (tadalafil) II-3

Levitra (vardenafil hydrochloride) II-3

Comparative Analysis II-3

Similarities II-3

Differences II-3

Side Effects II-3

2. PRODUCT OVERVIEW II-4

Introduction II-4

Erectile Dysfunction II-4

Pathophysiology II-4

Causes II-5

Symptoms II-5

Diagnosis II-6

Medical Diagnosis II-6

Patient History II-6

Physical Examination II-6

Laboratory Tests II-6

Other Tests II-7

Psychosocial Examination II-7

Clinical Tests II-7

Duplex Ultrasound II-7

Bulbocavernosus Reflex Test II-7

Nocturnal Penile Tumescence II-7

Penile Biothesiometry II-7

Penile Angiogram II-8

Corpus Cavernosometry II-8

Digital Subtraction Angiography (DSA) II-8

Magnetic Resonance Angiography II-8

Treatment II-8

Overview II-8

Psychotherapy II-9

Behavioral Changes II-9

Stop Smoking II-9

Control Cholesterol II-9

Reduction in Fat II-9

Oral Treatment II-10

Drug Therapy II-10

Other Non-Invasive Treatments II-10

Vacuum Constriction Device II-11

Minimal Invasive Therapies II-11

Surgery II-11

Penile Prostheses II-11

Arterial Surgery II-12

Venous Surgery II-12

Latest Advancements in Treatments II-12

Future Medications for Treatment of Erectile Dysfunction II-13

Alprostadil II-13

Apomorphine II-13

Meloncortin Stimulators II-13

Gene Therapy II-13

Unapproved and Controversial Treatments II-13

Naltrexone II-13

Bremelanotide II-13

Melanotan II II-14

hMaxi-K II-14

Enzyte II-14

Prelox II-14

Yohimbe II-14

Natural Remedies II-14

L-Arginine II-15

Ginkgo II-15

Ginseng II-15

Ashwagandha II-15

Cordiceps Sinensis II-15

Horny Goat Weed II-16

Chinese Angelica II-16

Pomegranate Juice II-16

3. RECENT INDUSTRY ACTIVITY II-17

Warner Chilcott Inks Agreement with Dong-A PharmTech II-17

Warner Chilcott Signs Agreement with NexMed II-17

Coloplast Establishes US Headquarters II-17

Vivus Commences Phase-III Trials of Avanafil II-17

Skreem Entertainment Inks Letter of Intent to Purchase EdMed II-18

Eli Lilly Receives FDA Approval for Cialis® II-18

Eli Lilly Partners with Sanofi-Aventis II-18

Deerfield Management Collaborates with Vivus II-18

Eli Lilly Purchases ICOS II-18

4. FOCUS ON SELECT PLAYERS II-19

Abbott Laboratories (US) II-19

Eli Lilly and Company, Inc. (US) II-19

F. Hoffmann-La Roche, Inc. (US) II-19

GlaxoSmithKline plc (UK) II-19

Nexmed, Inc. (US) II-20

Pfizer, Inc. (US) II-20

Sanofi-aventis SA (France) II-20

Vivus, Inc. (US) II-20

Warner Chilcott Limited (US) II-21

5. GLOBAL MARKET PERSPECTIVE II-22

Table 1: World Recent Past, Current & Future Analysis for

Erectile Dysfunction Drugs by Geographic Region - US, Canada,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2007 through 2015 (includes corresponding Graph/Chart) II-22

Table 2: World Historic Review for Erectile Dysfunction Drugs

by Geographic Region - US, Canada, Japan, Europe, and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) II-23

Table 3: World 13-Year Perspective for Erectile Dysfunction

Drugs by Geographic Region - Percentage Breakdown of Dollar

Sales for US, Canada, Japan, Europe, and Rest of World Markets

for Years 2003, 2009 & 2015 (includes corresponding

Graph/Chart) II-24

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Current & Future Analysis III-1

ED Market Witnesses Robust Demand III-1

User Base Expands with Better Understanding of Disease

Indications III-1

Lower Market Penetration Offers Growth Opportunities III-1

Lack of Insurance Coverage Affects ED Drug Sales III-2

Strategic Corporate Developments III-2

Select Players III-4

Abbott Laboratories III-4

Eli Lilly and Company, Inc. III-4

F. Hoffmann-La Roche, Inc. III-4

Nexmed, Inc. III-5

Pfizer, Inc. III-5

Vivus, Inc. III-5

Warner Chilcott Limited III-5

B.Market Analytics III-6

Table 4: US Recent Past, Current and Future Analysis for

Erectile Dysfunction Drugs Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-6

Table 5: US Historic Review for Erectile Dysfunction Drugs

Analyzed with Annual Sales Figures in US$ Million for Years

2001 through 2006 (includes corresponding Graph/Chart) III-6

2. CANADA III-7

Market Analysis III-7

Table 6: Canadian Recent Past, Current and Future Analysis

for Erectile Dysfunction Drugs Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-7

Table 7: Canadian Historic Review for Erectile Dysfunction

Drugs Analyzed with Annual Sales Figures in US$ Million for

Years 2001 through 2006 (includes corresponding Graph/Chart) III-7

3. JAPAN III-8

Market Analysis III-8

Table 8: Japanese Recent Past, Current and Future Analysis

for Erectile Dysfunction Drugs Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-8

Table 9: Japanese Historic Review for Erectile Dysfunction

Drugs Analyzed with Annual Sales Figures in US$ Million for

Years 2001 through 2006 (includes corresponding Graph/Chart) III-8

4. EUROPE III-9

A.Market Analysis III-9

Current & Future Analysis III-9

Market for Erectile Dysfunction Products to Rise III-9

Development of Novel Drugs for ED and Lifestyle Disorders III-9

B.Market Analytics III-10

Table 10: European Recent Past, Current and Future Analysis

for Erectile Dysfunction Drugs by Geographic Region -

France, Germany, Italy, UK, and Rest of Europe Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2007 through 2015 (includes corresponding Graph/Chart) III-10

Table 11: European Historic Review for Erectile Dysfunction

Drugs by Geographic Region - France, Germany, Italy, UK, and

Rest of Europe Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) III-11

Table 12: European 13-Year Perspective for Erectile

Dysfunction Drugs by Country/Region - Percentage Breakdown

of Dollar Sales for France, Germany, Italy, UK, and Rest of

Europe Markets for Years 2003, 2009 and 2015 III-12

4a. FRANCE III-13

A.Market Analysis III-13

Current & Future Analysis III-13

Sanofi-Aventis SA - A Major French Player III-13

B.Market Analytics III-13

Table 13: French Recent Past, Current and Future Analysis

for Erectile Dysfunction Drugs Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-13

Table 14: French Historic Review for Erectile Dysfunction

Drugs Analyzed with Annual Sales Figures in US$ Million for

Years 2001 through 2006 (includes corresponding Graph/Chart) III-14

4b. GERMANY III-15

Market Analysis III-15

Table 15: German Recent Past, Current and Future Analysis

for Erectile Dysfunction Drugs Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-15

Table 16: German Historic Review for Erectile Dysfunction

Drugs Analyzed with Annual Sales Figures in US$ Million for

Years 2001 through 2006 (includes corresponding Graph/Chart) III-15

4c. ITALY III-16

Market Analysis III-16

Table 17: Italian Recent Past, Current and Future Analysis

for Erectile Dysfunction Drugs Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-16

Table 18: Italian Historic Review for Erectile Dysfunction

Drugs Analyzed with Annual Sales Figures in US$ Million for

Years 2001 through 2006 (includes corresponding Graph/Chart) III-16

4d. UNITED KINGDOM III-17

A.Market Analysis III-17

Current & Future Analysis III-17

GlaxoSmithKline plc - A Major UK Player III-17

B.Market Analytics III-17

Table 19: UK Recent Past, Current and Future Analysis for

Erectile Dysfunction Drugs Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-17

Table 20: UK Historic Review for Erectile Dysfunction Drugs

Analyzed with Annual Sales Figures in US$ Million for Years

2001 through 2006 (includes corresponding Graph/Chart) III-18

4e. REST OF EUROPE III-19

A.Market Analysis III-19

Current & Future Analysis III-19

Strategic Corporate Development III-19

B.Market Analytics III-19

Table 21: Rest of Europe Recent Past, Current and Future

Analysis for Erectile Dysfunction Drugs Analyzed with Annual

Sales Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) III-19

Table 22: Rest of Europe Historic Review for Erectile

Dysfunction Drugs Analyzed with Annual Sales Figures in US$

Million for Years 2001 through 2006 (includes corresponding

Graph/Chart) III-20

5. REST OF WORLD III-21

Market Analysis III-21

Table 23: Rest of World Recent Past, Current and Future

Analysis for Erectile Dysfunction Drugs Analyzed with Annual

Sales Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) III-21

Table 24: Rest of World Historic Review for Erectile

Dysfunction Drugs Analyzed with Annual Sales Figures in US$

Million for Years 2001 through 2006 (includes corresponding

Graph/Chart) III-22

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 26 (including Divisions/Subsidiaries - 30)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 15

Japan 3

Europe 9

France 1

Germany 1

The United Kingdom 2

Rest of Europe 5

Asia-Pacific (Excluding Japan) 2

Middle East 1

------------------------------------------

To order this report:

Drug and Medication Industry: Global Erectile Dysfunction Drugs industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo